Ignite Creation Date:
2025-12-24 @ 11:25 PM
Ignite Modification Date:
2025-12-25 @ 9:10 PM
Study NCT ID:
NCT05289856
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2024-03-07
First Post:
2022-03-07
Is NOT Gene Therapy:
False
Has Adverse Events:
False
Brief Title:
Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3)
Sponsor:
Johannes Gutenberg University Mainz
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-03-28
Start Date Type:
ACTUAL
Primary Completion Date:
2025-03-01
Primary Completion Date Type:
ESTIMATED
Completion Date:
2025-12-01
Completion Date Type:
ESTIMATED
First Submit Date:
2022-03-07
First Submit QC Date:
None
Study First Post Date:
2022-03-22
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-03-05
Last Update Post Date:
2024-03-07
Last Update Post Date Type:
ACTUAL